Annovis Bio Inc (ANVS)

[McMagyar]

Hello, and welcome to Annovis, a very exciting Pharma with a tremendous multi-pronged(4)strategy to attack the ravages of CNS disease.
Early 28 patient (14 Parkinsons and 14 Alzheimers) results are expected within first quarter of 2021. It is a low float Equity(only 7,000,000 shares total) less in Float, and as of February of 2021 the company is MC valued at around $140 Million. Minimum Valuations in My Opinion for successful Dementia -Candidates- are closer to the $1-$3 Billion range,
with higher valuations the closer these drugs come to market.
There are early indications that Annovis expects positive results from this 28 patient cohort as they have filed up to a $250,000,000 shelf registration.

There are currently two drugs which offer great hope in this category, one from Anavex and one from Cassava. We may only hope for more candidates like Annovis to be successful.